Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Spark Biopharma Inc. has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 distinct examiner and 1 distinct art unit, creating a direct examination path for the pending application.
HASTINGS, ALISON AZAR is the busiest examiner, with 1 pending matter. The examiner and art-unit assignments identify the complete current prosecution setting. Counsel can focus resources on the record before that examiner, align the response with the applicable biotechnology and pharmaceutical examination issues, and monitor the matter without needing to coordinate across multiple current assignments.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HASTINGS, ALISON AZAR | 1 | 62.5% | +42.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18687534 | CANCER IMMUNOTHERAPY COMPOSITION CONTAINING INTERACTION INHIBITOR OF STING AND TRIM29 AS ACTIVE INGREDIENT | HASTINGS, ALISON AZAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18687534 | CANCER IMMUNOTHERAPY COMPOSITION CONTAINING INTERACTION INHIBITOR OF STING AND TRIM29 AS ACTIVE INGREDIENT | HASTINGS, ALISON AZAR | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18687534 | CANCER IMMUNOTHERAPY COMPOSITION CONTAINING INTERACTION INHIBITOR OF STING AND TRIM29 AS ACTIVE INGREDIENT | HASTINGS, ALISON AZAR | 1627 | §102§112 | Non-Final OA | — | Pending | Feb 28, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSpark Biopharma Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Alison Azar Hastings has the most, with 1 of Spark Biopharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
